TY  - GEN
AU  - Kater,Arnon P
AU  - Kersting,Sabina
AU  - van Norden,Yvette
AU  - Dubois,Julie
AU  - Dobber,Johan A
AU  - Mellink,Clemens H
AU  - Evers,Ludo M
AU  - Croon-de Boer,Fransien
AU  - Schreurs,John
AU  - van der Spek,Ellen
AU  - Visser,Hein
AU  - Idink,Cecile
AU  - Wittebol,Shulamiet
AU  - Hoogendoorn,Mels
AU  - Tonino,Sanne H
AU  - Mobasher,Mehrdad
AU  - Levin,Mark-David
TI  - Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
SN  - 2473-9537
PY  - 2019///0923
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - adverse effects
KW  - Antineoplastic Agents
KW  - Bridged Bicyclo Compounds, Heterocyclic
KW  - therapeutic use
KW  - Drug Administration Schedule
KW  - Drug Therapy, Combination
KW  - Female
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Neoplasm, Residual
KW  - Remission Induction
KW  - Risk Factors
KW  - Sulfonamides
KW  - Tumor Lysis Syndrome
KW  - etiology
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/bloodadvances.2018019422
ER  -